お知らせ • May 05
Race Oncology Limited Announces Change of Chief Medical Officer, Effective May 5, 2025 Race Oncology Limited announced the appointments of Dr. Jose Iglesias, who succeeds Dr. Michelle Rashford as Chief Medical Officer (CMO), effective 5 May 2025. Dr. Jose Iglesias is an internationally recognized pharmaceutical executive with a distinguished career spanning both major and emerging pharmaceutical companies. His appointment marks a significant addition to Race's clinical leadership team. Dr. Iglesias held key leadership roles at Abraxis BioScience, including Vice President of Global Clinical Development and Chief Medical Officer, where he oversaw the global development of the reformulated chemotherapeutic agent, Abraxane® (paclitaxel) and other pipeline assets. He later served as Vice President of Clinical Development at Celgene, successfully leading several Phase 3 clinical programs for Abraxane® in pancreatic, lung, and metastatic breast cancers. Dr. Iglesias has also held senior medical leadership roles at Amgen, Bionomics, Biothera Pharmaceuticals, Apobiologix, and Eli Lilly, including as Head of Clinical Studies at Eli Lilly Australia. His has extensive experience interacting with global regulatory authorities, reimbursement agencies, oncology cooperative groups, and patient advocacy organizations. He serves as an independent oncology consultant, specializing in solid tumour oncology, immuno-oncology, and translational medicine, with a focus on early to mid-phase clinical development. A widely published expert in oncology, Dr. Iglesias's work has garnered over 12,000 citations. お知らせ • Apr 03
Race Oncology Limited Announces RC220 Phase 1 Trial Opens for Patient Enrolment Race Oncology Limited (Race) announced the site activation of Southside Cancer Care Centre (Miranda, NSW) after receiving governance approval enabling the commencement of patient enrolment for its Phase 1 clinical trial of RC220 in combination with doxorubicin in advanced solid tumours patients. This follows the receipt of human ethics approval, undertaking site initiation, and completion of all documentation. The Phase 1 trial will be open label and conducted across multiple sites in Australia, Hong Kong and South Korea. The trial will use ascending doses of RC220 in up to 33 patients to determine the safety, tolerability, pharmacokinetics, maximum tolerated combined dose (MTCD) in combination with doxorubicin, and effects on a range of clinical biomarkers including m6A RNA. After an interim analysis of the data, the optimal dosage of RC220 in combination with doxorubicin will be assessed in an additional 20 patients for further safety, tolerability, and preliminary cardioprotective and anticancer efficacy signals. The Phase 1 trial will use a Bayesian design enabling greater trial flexibility and speed than traditional approaches. A recent meta-analysis of single agent doxorubicin treatment undertaken by Race Oncology has identified an anticancer response rate to doxorubicin of up to 35% in a wide range of advance and metastatic solid tumour cancers including breast cancer, small cell lung cancer, ovarian cancer, bladder cancer, liver cancer, endometrial cancer, upper gastrointestinal cancer, thyroid cancer, non-small cell lung cancer, and prostate cancer. Preclinical studies by Race Oncology have identified enhancement of the cancer killing activity of doxorubicin by the active anticancer agent in RC220 in 85% of 143 diverse cancer cell lines screened. Timing of first patient enrolment is subject to patient suitability and their interest in participating in the trial. お知らせ • Mar 31
Race Oncology Limited Receives HREC Approval from Bellberry to Commence its RC220 Phase 1 Clinical Trial at Gosford and Wyong Hospitals Race Oncology Limited announced that it has received HREC approval from Bellberry to commence its RC220 Phase 1 clinical trial at Gosford and Wyong Hospitals (Central Coast Local Health District). HREC approval allows both the Gosford and Wyong Hospitals to enrol patients subject to final site approvals and activation. These approvals are expected during the month of April. The RAC-010 clinical trial is designed to assess the safety, tolerability and pharmacokinetics (PK) of RC220 alone and in combination with doxorubicin, in patients with solid tumours. This approval follows recent HREC approval for the Southside Cancer Centre (Miranda). It is expected HREC approval will be received for additional trial sites in Australia, Hong Kong and South Korea over the following months. お知らせ • Oct 07
Race Oncology Limited, Annual General Meeting, Nov 25, 2024 Race Oncology Limited, Annual General Meeting, Nov 25, 2024. Location: at the dixon room, state library nsw, 1 shakespeare place, new south wales, australia., sydney Australia お知らせ • Nov 22
Race Oncology Limited Appoints Daniel Tillett as Chief Executive Officer Race Oncology Limited announced that Dr Daniel Tillett has been appointed full-time Chief Executive Officer, effective immediately. Dr Tillett will work alongside Executive Director, Dr Pete Smith, to advance the Company's strategic, clinical and commercialization plans for bisantrene. From September 2019 to March 2023, Dr Tillett was Race's Chief Scientific Officer and Executive Director. He has most recently been working with the Company in a consultancy capacity. In addition to his extensive experience with Race and bisantrene, Dr Tillett brings more than 25 years of experience in the biotech industry and is the founder and CEO of Nucleics, an Australian biotechnology company focused on DNA sequencing and genomics. He was a tenured academic (Senior Lecturer) within the School of Pharmacy and Applied Science at La Trobe University, Australia teaching and researching in the areas of phage therapy (bacterial virology), pharmacy, environmental microbiology, bioinformatics and cancer. お知らせ • Oct 10
Race Oncology Limited, Annual General Meeting, Nov 27, 2023 Race Oncology Limited, Annual General Meeting, Nov 27, 2023, at 12:00 AUS Eastern Standard Time. Location: the Dixon Room, State Library NSW, 1 Shakespeare Place Sydney New South Wales Australia Agenda: To consider the re-election and appointment of Directors. 
